{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:57:53Z","timestamp":1790452673386,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cerebral amyloid angiopathy (CAA) is most commonly associated with \u03b2-amyloid deposition, but other amyloid proteins may accumulate in leptomeningeal and superficial cortical vessels. We report a man first evaluated neurologically at 44 years of age after approximately one year of recurrent upper-limb and perioral sensory symptoms with speech disturbance, retrospectively considered transient focal neurological episodes (TFNEs). During follow-up, he developed bilateral vitritis and progressive behavioral, psychiatric, and cognitive impairment. Brain computed tomography showed diffuse linear and serpiginous leptomeningeal hyperdensities, consistent with calcified amyloid deposits with focal cortical subarachnoid hemorrhagic lesions SAH); angiography showed no underlying vascular abnormality. Follow-up neuroimaging demonstrated persistent leptomeningeal abnormalities and hemorrhagic lesions. Leptomeningeal biopsy revealed Congo red- and thioflavin S-positive vascular and meningeal amyloid deposits, with negative \u03b2-amyloid and amyloid A immunohistochemistry. A subcutaneous adipose tissue biopsy supported systemic amyloid deposition, and genetic testing identified the heterozygous TTR c.265T\u2009&gt;\u2009C, p.(Tyr89His) variant. Electroneurography showed no large-fiber peripheral neuropathy. An off-label trial of tolcapone produced no clinical benefit. The patient subsequently developed severe cognitive and functional disability and progressive hydrocephalus, and died at 55 years of age from acute respiratory failure. This case highlights TTR-related cerebral amyloid angiopathy (TTR-CAA) as an important non-\u03b2-amyloid cause of TFNEs, calcified leptomeningeal infiltration, focal superficial hemorrhage, and progressive neuropsychiatric decline.<\/jats:p>","DOI":"10.1007\/s10072-026-09398-2","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:19:24Z","timestamp":1790403564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond \u03b2-amyloid: transthyretin cerebral amyloid angiopathy"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-2171","authenticated-orcid":false,"given":"Carla","family":"Vera-C\u00e1ceres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Montecino","family":"Romanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat Gonz\u00e1lez","family":"Platas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"S\u00e1nchez-Miranda Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto L\u00f3pez","family":"Traba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeilen","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel D\u00edaz","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azuquahe P\u00e9rez","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatr\u00edz B\u00e1ez","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daysi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"9398_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00401-022-02501-9","volume":"145","author":"R Taipa","year":"2023","unstructured":"Taipa R, Sousa L, Pinto M, Reis I, Rodrigues A, Oliveira P, Melo-Pires M, Coelho T (2023) Neuropathology of central nervous system involvement in TTR amyloidosis. Acta Neuropathol 145:113\u2013126","journal-title":"Acta Neuropathol"},{"key":"9398_CR2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","volume":"97","author":"L Sousa","year":"2021","unstructured":"Sousa L, Coelho T, Taipa R (2021) CNS involvement in hereditary transthyretin amyloidosis. Neurology 97:1111\u20131119. https:\/\/doi.org\/10.1212\/WNL.0000000000012965","journal-title":"Neurology"},{"key":"9398_CR3","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1212\/01.WNL.0000065901.18353.AB","volume":"60","author":"G Blevins","year":"2003","unstructured":"Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi Asl K, Benson MD, Donat JR (2003) Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 60:1625\u20131630","journal-title":"Neurology"},{"key":"9398_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M (2020) Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 9:317\u2013333","journal-title":"Neurol Ther"},{"key":"9398_CR5","doi-asserted-by":"crossref","unstructured":"Mathieu F et al (2018) Oculoleptomeningeal amyloidosis secondary to the rare transthyretin c.381T\u2009>\u2009G (p.Ile127Met) mutation. World Neurosurg","DOI":"10.1016\/j.wneu.2017.12.096"},{"key":"9398_CR6","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66:2451\u20132466","journal-title":"J Am Coll Cardiol"},{"key":"9398_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF et al (2022) The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 21:714\u2013725","journal-title":"Lancet Neurol"},{"key":"9398_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neurol.2025.07.012","volume":"181","author":"JB Brunet de Courssou","year":"2025","unstructured":"Brunet de Courssou JB, Gorza L, Babin M, Nasser G, Ancelet C, Labeyrie C, Denier C, Cauquil C (2025) Transthyretin variant cerebral amyloid angiopathy fulfilling the modified Boston criteria: retrospective data from the Bic\u00eatre hospital cohort. Rev Neurol (Paris) 181:801\u2013807","journal-title":"Rev Neurol (Paris)"},{"key":"9398_CR9","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1161\/STROKEAHA.121.038451","volume":"53","author":"D Chen","year":"2022","unstructured":"Chen D, Zhang C, Parikh N, Merkler AE, Navi BB, Fink ME et al (2022) Association between systemic amyloidosis and intracranial hemorrhage. Stroke 53:e92\u2013e93. https:\/\/doi.org\/10.1161\/STROKEAHA.121.038451","journal-title":"Stroke"},{"key":"9398_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnen\/nlaa075","volume":"79","author":"GS Quintanilha","year":"2020","unstructured":"Quintanilha GS, Cruz MW, Silva MTT, Chimelli L (2020) Oculoleptomeningeal amyloidosis due to transthyretin p.Y89H (Y69H) variant. J Neuropathol Exp Neurol 79:1134\u20131136. https:\/\/doi.org\/10.1093\/jnen\/nlaa075","journal-title":"J Neuropathol Exp Neurol"},{"key":"9398_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/febs.15339","volume":"288","author":"F Pinheiro","year":"2021","unstructured":"Pinheiro F, Varej\u00e3o N, Esperante S, Santos J, Vel\u00e1zquez-Campoy A, Reverter D, Pallar\u00e8s I, Ventura S (2021) Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. FEBS J 288:310\u2013324. https:\/\/doi.org\/10.1111\/febs.15339","journal-title":"FEBS J"},{"key":"9398_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/13506129.2022.2056011","volume":"29","author":"Y Takahashi","year":"2022","unstructured":"Takahashi Y, Ohashi N, Takasone K, Yoshinaga T, Yazaki M, Roberts M, Glidden PF, Sekijima Y (2022) CSF\/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. Amyloid 29:190\u2013196. https:\/\/doi.org\/10.1080\/13506129.2022.2056011","journal-title":"Amyloid"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09398-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:02:32Z","timestamp":1790449352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09398-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9398"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09398-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient\u2019s family for publication of this case report and the accompanying images.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"816"}}